Mercer Global Advisors Inc. ADV trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 13.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,654 shares of the company’s stock after selling 257 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Medpace were worth $351,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Wasatch Advisors Inc. increased its stake in Medpace by 12.1% during the 1st quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock worth $446,338,000 after buying an additional 294,103 shares during the period. Jacobs Levy Equity Management Inc. boosted its stake in shares of Medpace by 2,058.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 287,194 shares of the company’s stock valued at $45,138,000 after buying an additional 273,887 shares during the last quarter. Thrivent Financial for Lutherans grew its position in shares of Medpace by 144.4% during the fourth quarter. Thrivent Financial for Lutherans now owns 369,939 shares of the company’s stock worth $78,578,000 after buying an additional 218,554 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Medpace by 32.4% in the second quarter. Goldman Sachs Group Inc. now owns 390,038 shares of the company’s stock worth $58,377,000 after buying an additional 95,524 shares during the last quarter. Finally, Channing Capital Management LLC raised its holdings in Medpace by 45.3% in the third quarter. Channing Capital Management LLC now owns 231,460 shares of the company’s stock valued at $36,379,000 after acquiring an additional 72,149 shares in the last quarter. 82.49% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Medpace
In other news, CEO August J. Troendle sold 31,648 shares of the stock in a transaction on Tuesday, April 25th. The stock was sold at an average price of $221.83, for a total value of $7,020,475.84. Following the completion of the transaction, the chief executive officer now owns 6,451,371 shares of the company’s stock, valued at $1,431,107,628.93. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 25.70% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Medpace Stock Performance
Shares of MEDP opened at $202.64 on Thursday. The firm has a fifty day moving average of $195.65 and a 200-day moving average of $206.79. The company has a market cap of $6.18 billion, a price-to-earnings ratio of 25.65 and a beta of 1.42. Medpace Holdings, Inc. has a 1 year low of $130.62 and a 1 year high of $241.48.
Medpace (NASDAQ:MEDP – Get Rating) last posted its earnings results on Monday, April 24th. The company reported $2.27 EPS for the quarter, topping the consensus estimate of $1.76 by $0.51. The firm had revenue of $434.07 million during the quarter, compared to analysts’ expectations of $402.83 million. Medpace had a net margin of 16.44% and a return on equity of 75.20%. Medpace’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.69 EPS. Analysts predict that Medpace Holdings, Inc. will post 8.11 EPS for the current year.
Medpace Company Profile
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.